Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Retained Earnings (2017 - 2025)

Historic Retained Earnings for Autolus Therapeutics (AUTL) over the last 9 years, with Q3 2025 value amounting to -$1.3 billion.

  • Autolus Therapeutics' Retained Earnings fell 2097.78% to -$1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.3 billion, marking a year-over-year decrease of 2097.78%. This contributed to the annual value of -$1.1 billion for FY2024, which is 2511.63% down from last year.
  • As of Q3 2025, Autolus Therapeutics' Retained Earnings stood at -$1.3 billion, which was down 2097.78% from -$1.2 billion recorded in Q2 2025.
  • In the past 5 years, Autolus Therapeutics' Retained Earnings registered a high of -$412.5 million during Q1 2021, and its lowest value of -$1.3 billion during Q3 2025.
  • In the last 5 years, Autolus Therapeutics' Retained Earnings had a median value of -$755.5 million in 2023 and averaged -$802.7 million.
  • Its Retained Earnings has fluctuated over the past 5 years, first crashed by 5448.48% in 2021, then tumbled by 2097.78% in 2025.
  • Autolus Therapeutics' Retained Earnings (Quarter) stood at -$521.3 million in 2021, then fell by 28.55% to -$670.2 million in 2022, then tumbled by 31.09% to -$878.6 million in 2023, then fell by 25.12% to -$1.1 billion in 2024, then decreased by 17.94% to -$1.3 billion in 2025.
  • Its last three reported values are -$1.3 billion in Q3 2025, -$1.2 billion for Q2 2025, and -$1.2 billion during Q1 2025.